<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vascular malformations of the central nervous system
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vascular malformations of the central nervous system
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vascular malformations of the central nervous system
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert J Singer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher S Ogilvy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Guy Rordorf, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            José Biller, MD, FACP, FAAN, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION AND TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral vascular malformations refer to a group of conditions characterized by abnormal vascular configurations occurring within the brain (and spinal cord). As a group, they occur in 0.1 to 4.0 percent of the general population [
         <a href="#rid1">
          1-3
         </a>
         ]. Four general subtypes of congenital malformations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arteriovenous malformations (AVMs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cavernous malformations (CMs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Developmental venous anomalies (DVAs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Capillary telangiectasias
        </p>
        <p>
        </p>
        <p>
         AVMs may be subcategorized into pial AVMs and dural arteriovenous fistulas. Cavernous malformations have also been called cavernous angiomas, cavernous hemangiomas, and cavernomas. Developmental venous anomalies were previously also called venous angiomas.
        </p>
        <p>
         Developmental venous anomalies are most common in autopsy series, with an incidence of 2 percent [
         <a href="#rid4">
          4,5
         </a>
         ]. This is followed by arteriovenous malformations (1 percent), capillary telangiectasias (0.7 percent), and cavernous malformations (0.4 percent). Developmental venous anomalies and capillary telangiectasia are usually benign, while cavernous malformations and arteriovenous malformations have a greater tendency toward neurologic sequelae.
        </p>
        <p>
         This topic will review cavernous malformations, developmental venous anomalies, and capillary telangiectasias. Cerebral and spinal cord arteriovenous malformations and carotid-cavernous fistulas are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">
          "Brain arteriovenous malformations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord", section on 'Vascular malformations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14161.html" rel="external">
          "Carotid-cavernous fistulas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3433067380">
         <span class="h1">
          ARTERIOVENOUS MALFORMATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arteriovenous malformations are the most dangerous congenital vascular malformations. This topic is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">
          "Brain arteriovenous malformations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          CAVERNOUS MALFORMATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2754771344">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cavernous malformations (CMs) may occur sporadically or in a familial pattern [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1284156232">
         <span class="h3">
          Familial CMs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial CM cases have an autosomal dominant inheritance pattern and are estimated to account for approximately 20 percent of all cases of CMs. Most familial cases have multiple CMs. Pathogenic variants in
         <em>
          CCM1
         </em>
         (
         <em>
          KRIT1
         </em>
         ),
         <em>
          CCM2
         </em>
         , and
         <em>
          CCM3
         </em>
         (
         <em>
          PDCD10
         </em>
         ) are known to cause familial CMs [
         <a href="#rid7">
          7-9
         </a>
         ]. The CCM proteins encoded by these three genes interact with each other and are involved with cellular signaling pathways, including formation of a CCM complex signaling platform. Loss of CCM proteins results in the dysregulation of signaling pathways in brain endothelial cells and eventual lesion formation [
         <a href="#rid10">
          10,11
         </a>
         ]. Most of the pathogenic variants constitute loss-of-function mutations involving nonsense, frameshift, or splice site mutations, but larger deletions and duplications have also been reported [
         <a href="#rid6">
          6,9,12
         </a>
         ].
        </p>
        <p>
         Nearly all familial cases of cerebral CMs among Hispanic Americans have been linked to a founder variant of
         <em>
          KRIT1
         </em>
         [
         <a href="#rid13">
          13-15
         </a>
         ]. Familial cases in non-Hispanic White families have been linked to
         <em>
          CCM2
         </em>
         [
         <a href="#rid16">
          16
         </a>
         ] and
         <em>
          PDCD10
         </em>
         [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
         CM may also be found in some patients with genetic conditions such as hereditary hemorrhagic telangiectasia. (See
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H712617857">
         <span class="h3">
          Sporadic CMs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 80 percent of CMs are sporadic [
         <a href="#rid18">
          18
         </a>
         ]. Most sporadic cerebral CMs present as solitary lesions and are often associated with a developmental venous anomaly (DVA), but sporadic CMs occasionally present as multiple lesions around the periphery of a DVA [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Sporadic CMs appear to be acquired lesions. De novo CMs have been demonstrated on serial magnetic resonance imaging (MRI) [
         <a href="#rid19">
          19
         </a>
         ]. CMs may also develop after cranial radiation therapy [
         <a href="#rid20">
          20
         </a>
         ]. Genetic susceptibilities may underly the development of CMs in some patients [
         <a href="#rid21">
          21,22
         </a>
         ]. Novel genetic variants in the CCM pathway were identified in one series of patients with sporadic CMs [
         <a href="#rid23">
          23
         </a>
         ]. In a cohort of 88 patients with sporadic CM, nearly 40 percent were found to have a somatic variant in the
         <em>
          PIK3CA
         </em>
         oncogene, compared with 10 percent with a variant in a CCM gene [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2102062622">
         <span class="h2">
          Neuropathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         On gross examination, CMs have a characteristic "mulberry" or "popcorn" appearance with engorged purplish clusters. They vary from 2 mm to several centimeters in diameter. Microscopic examination reveals that CMs are composed of dilated, thin-walled capillaries with a simple endothelial lining and a thin, fibrous adventitia. Elastic fibers and smooth muscle are not present in the vessel walls. In the classic description of CMs, there is no intervening brain tissue between the channels of the lesion [
         <a href="#rid24">
          24
         </a>
         ]. However, this may not be an essential criterion of CMs, as one histopathologic study of 71 CM cases noted intervening brain parenchyma in 50 (70 percent) [
         <a href="#rid25">
          25
         </a>
         ], and others have also noted intervening brain tissue in some fraction of cases [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         The immediately surrounding tissue is usually gliotic and hemosiderin laden due to previous hemorrhages. It contains dilated capillaries that may represent telangiectasias; this finding supports the integrative concept of capillary telangiectasias and CMs representing two ends of a spectrum in the development of CMs [
         <a href="#rid26">
          26
         </a>
         ]. Inflammation, calcification, and, rarely, ossification may be identified with CMs, usually in larger lesions [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The cerebrum is the most common location for CMs (70 to 90 percent) [
         <a href="#rid29">
          29
         </a>
         ]. They have been reported throughout the supratentorial compartment, but most commonly are subcortical and predisposed to the rolandic and temporal areas. Posterior fossa lesions comprise approximately 25 percent of CMs in most large series, with the majority located in the pons and cerebellar hemispheres. Spinal cord CMs are intramedullary lesions and predominantly involve the cervical and thoracic regions [
         <a href="#rid30">
          30,31
         </a>
         ]. Intramedullary spinal cord CMs are more common than once recognized, with over 600 cases reported in a meta-analysis published in 2014 [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         DVAs may be associated with CMs, particularly in sporadic cases [
         <a href="#rid32">
          32-35
         </a>
         ]. In a series of 102 patients, DVAs associated with CMs were found in 23 percent; these occurred more often with lesions in the posterior fossa than the supratentorial compartment [
         <a href="#rid32">
          32
         </a>
         ]. A later series of 57 patients with CMs found associated DVAs in 25 percent, and atypical patterns of venous drainage associated with CMs were seen in an additional 35 percent [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Developmental venous anomalies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1229570554">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of CMs is 0.15 to 0.56 per 100,000 in various populations [
         <a href="#rid36">
          36
         </a>
         ]. CMs occur with equal frequency in males and females, with a mean age of 30 to 40, although females more commonly present with hemorrhage and neurologic deficits [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p>
         CMs may occur sporadically or in a familial pattern. (See
         <a class="local">
          'Familial CMs'
         </a>
         above and
         <a class="local">
          'Sporadic CMs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presentation of CMs is specific to their location. A substantial proportion are asymptomatic and are found incidentally on brain MRI [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supratentorial CMs commonly present with hemorrhage, seizures, and progressive neurologic deficits. Annual bleeding rates of 0.25 to 1.1 percent have been reported in several large series [
         <a href="#rid38">
          38,42
         </a>
         ]. Seizures and progressive neurologic deficits may be the result of mass effect and secondary compromise of the microcirculation or the result of microhemorrhages with local hemosiderin deposition irritating cortical or subcortical tissue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infratentorial CMs commonly present with hemorrhage and progressive neurologic deficits. Lesions in the brainstem present with cranial neuropathies and long-tract signs that cause progressive neurologic decline due to the high volume of critical nuclei and fiber tracts in this area. Thus, the natural history of brainstem lesions is worse than that of lesions in other areas. The annual bleeding rate for brainstem lesions is 2 to 3 percent per year, with recurrent hemorrhage rates approaching 17 to 21 percent [
         <a href="#rid19">
          19
         </a>
         ]. Progressive neurologic decline is observed in 39 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2795936230">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI plays a key role in the identification and diagnosis of CMs [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Confirming the diagnosis'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI
         </strong>
         – Characteristic findings on T1- and T2-weighted images include a "popcorn" pattern of variable image intensities consistent with evolving blood products  (
         <a class="graphic graphic_diagnosticimage graphicRef80348" href="/z/d/graphic/80348.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef139103" href="/z/d/graphic/139103.html" rel="external">
          image 2
         </a>
         ). A dark hemosiderin ring, best seen on T2 or gradient echo sequences at the periphery of the lesion, is suggestive of remote hemorrhage  (
         <a class="graphic graphic_diagnosticimage graphicRef68000" href="/z/d/graphic/68000.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MRI should include gradient echo or susceptibility-weighted imaging  (
         <a class="graphic graphic_diagnosticimage graphicRef122720" href="/z/d/graphic/122720.html" rel="external">
          image 4
         </a>
         ), which may detect smaller CMs that are not visible on conventional MRI sequences [
         <a href="#rid6">
          6,44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Contrast-enhanced images should be obtained once a CM is identified in order to delineate any potential associated DVAs [
         <a href="#rid32">
          32
         </a>
         ]. Contrast-enhanced and susceptibility-weighted imaging sequences often demonstrate DVAs since they are associated with a classic "caput medusae" morphology and draining (or "collector") vein  (
         <a class="graphic graphic_diagnosticimage graphicRef122722" href="/z/d/graphic/122722.html" rel="external">
          image 5
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef139104" href="/z/d/graphic/139104.html" rel="external">
          image 6
         </a>
         ). On the other hand, CMs may have only scattered enhancement that is variable and inconsequential. This is critical in surgical planning since the resection of DVAs may compromise normal cortical venous drainage patterns and lead to venous infarction [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Developmental venous anomalies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CT
         </strong>
         – Computed tomography (CT) usually demonstrates a nonspecific, irregular, hyperdense mass from variable degrees of calcification  (
         <a class="graphic graphic_diagnosticimage graphicRef139104" href="/z/d/graphic/139104.html" rel="external">
          image 6
         </a>
         ). A faint perilesional blush with contrast administration is a variable and nonspecific finding.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4183299522">
         <span class="h2">
          Evaluation and diagnosis
         </span>
        </p>
        <p class="headingAnchor" id="H2597663544">
         <span class="h3">
          Confirming the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of CMs is based upon the characteristic radiologic appearance on MRI (see
         <a class="local">
          'Neuroimaging'
         </a>
         above). The diagnosis of familial CM is based upon detection of a pathogenic variant in one of the three genes (
         <em>
          KRIT1
         </em>
         ,
         <em>
          CCM2
         </em>
         , or
         <em>
          PDCD10
         </em>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Catheter angiography is generally not recommended for the detection of CMs unless arteriovenous malformation is a diagnostic consideration [
         <a href="#rid6">
          6
         </a>
         ]. Blood flow through CMs is minimal. Thus, they may not be seen on angiography and have been referred to as "angiographically occult." CMs demonstrate a capillary blush or early draining vein in approximately 10 percent of patients [
         <a href="#rid29">
          29
         </a>
         ]. These findings may be similar to the angiographic appearance of meningiomas.
        </p>
        <p class="headingAnchor" id="H2717149723">
         <span class="h3">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic testing for pathogenic variants in
         <em>
          CCM1
         </em>
         (
         <em>
          KRIT1
         </em>
         ),
         <em>
          CCM2
         </em>
         , and
         <em>
          CCM3
         </em>
         (
         <em>
          PDCD10
         </em>
         ) is indicated for patients with multiple CMs on imaging, a history of brain radiation therapy, or a positive family history of CMs [
         <a href="#rid6">
          6
         </a>
         ]. Testing should include direct sequencing and deletion/duplication analysis.
        </p>
        <p>
         For new cases of CMs, clinicians should obtain a three-generation family history at the time of diagnosis, with particular attention to family members with a history of hemorrhagic stroke, abnormal MRI scan, epilepsy, or other neurologic complications [
         <a href="#rid6">
          6
         </a>
         ]. However, family history may be confounded by the incomplete penetrance and variable presentation, even within families, of familial CMs.
        </p>
        <p class="headingAnchor" id="H279308320">
         <span class="h3">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lesions that mimic CMs on MRI include hemorrhagic or calcified neoplastic lesions, particularly hemorrhagic metastases (eg, melanoma, renal cell carcinoma), oligodendrogliomas, pleomorphic xanthoastrocytomas, polymorphous low-grade neuroepithelial tumor of the young, and cerebral microbleeds [
         <a href="#rid6">
          6,47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastases
         </strong>
         – Radiologic features more suggestive of metastases include associated extensive cerebral edema compared with the size of the lesion, localization at the junction of the gray and white matter, and/or heterogeneous contrast enhancement. (See
         <a class="medical medical_review" href="/z/d/html/5217.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of brain metastases", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gliomas
         </strong>
         – Low-grade gliomas in adults generally are expansile lesions involving both cortex and underlying white matter that appear hyperintense on MRI T2/fluid-attenuated inversion recovery (FLAIR) sequences. Vasogenic edema is usually absent, and most low-grade gliomas are nonenhancing. Calcification is sometimes present. (See
         <a class="medical medical_review" href="/z/d/html/5186.html" rel="external">
          "Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas", section on 'Neuroimaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pleomorphic xanthoastrocytomas
         </strong>
         – Pleomorphic xanthoastrocytoma is a rare type of brain tumor; the few reported lesions with MRI imaging were cortical with leptomeningeal involvement and either a solid or mixed solid-cystic appearance, with the solid component generally hypo- or isointense on T1 sequences, iso- or hyperintense on T2 sequences, and with postcontrast enhancement [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Pleomorphic xanthoastrocytoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polymorphous low-grade neuroepithelial tumors
         </strong>
         – Polymorphous low-grade neuroepithelial tumor of the young is an epileptogenic tumor characterized by oligodendroglioma-like morphology, aberrant expression of CD34 and genetic alterations in the
         <em>
          MAP
         </em>
         kinase pathway. It is typically a well-circumscribed lesion with macroscopic calcification and cystic component located peripherally in the posteroinferior temporal lobe in children and young adults (median age of 16 years) [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Polymorphous low-grade neuroepithelial tumor of the young'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral microbleeds
         </strong>
         – Multiple cerebral microbleeds can be seen with multiple CMs as well as cerebral amyloid angiopathy or hypertensive vasculopathy. These conditions generally can be distinguished from multiple CMs by the clinical setting and distribution of microbleeds. Microbleeds restricted to the cerebral cortex or superficial cerebellar regions (cerebellar cortex and vermis) suggest cerebral amyloid angiopathy, while microbleeds that primarily arise from the basal ganglia, thalamus, or pons suggest hypertensive vasculopathy. (See
         <a class="medical medical_review" href="/z/d/html/1128.html" rel="external">
          "Cerebral amyloid angiopathy", section on 'Microbleeds'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general management of CMs involves assessing the individual risk of future bleeding or other neurologic sequela. Most CMs are treated conservatively.
        </p>
        <p>
         The routine care and additional screening for patients with CM associated with other conditions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1112.html" rel="external">
          "Moyamoya disease and moyamoya syndrome: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H603229793">
         <span class="h3">
          Asymptomatic lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic CMs are observed, irrespective of location [
         <a href="#rid6">
          6
         </a>
         ]. Management of asymptomatic CMs involves annual clinical follow-up with a specialist (eg, neurologist or neurosurgeon) [
         <a href="#rid9">
          9
         </a>
         ]. Some experts advocate annual imaging with brain MRI [
         <a href="#rid50">
          50
         </a>
         ], but such an approach would not change management for patients who are asymptomatic.
        </p>
        <p>
         Immediate brain MRI is indicated for those who develop symptoms possibly related to CMs (eg, seizure, new headache, or new or progressive neurologic deficit) to evaluate for new hemorrhage or new CM [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         We agree that surgical resection is not recommended for asymptomatic CMs. However, some experts advise that surgical resection of a solitary asymptomatic cerebral CM located in an easily accessible noneloquent area may be considered for various reasons including prevention of future hemorrhage, reduction of burden caused by associated psychological disability and/or expensive and time-consuming follow-up visits, facilitation of lifestyle or career decisions, or risk reduction for patients who need anticoagulation [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2270652223">
         <span class="h3">
          Symptomatic lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, acute intracerebral hemorrhage (ICH) due to a CM is evaluated and managed in the same way as ICH from other causes. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         A summary of the general approach to symptomatic CMs according to presentation is as follows [
         <a href="#rid6">
          6,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-time seizure
         </strong>
         – Medical therapy with antiseizure medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medically refractory epilepsy
         </strong>
         – Surgical resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supratentorial CM with first ICH
         </strong>
         – Surgical resection if accessible lesion and symptomatic hemorrhage. Consideration for conservative management is given based on comorbidities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brainstem or deep nucleus CM with first ICH
         </strong>
         – Conservative management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brainstem or deep nucleus CM with second or greater ICH
         </strong>
         – Surgical resection (or possibly stereotactic radiosurgery, except for familial cases).
        </p>
        <p>
        </p>
        <p>
         Indications for surgical resection of accessible symptomatic cerebral and cerebellar lesions include progressive neurologic deficit, intractable epilepsy, and recurrent hemorrhage.
        </p>
        <p class="headingAnchor" id="H4068193699">
         <span class="h4">
          Risk of new or recurrent hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions about CM management should be guided by risk estimates of new or recurrent CM-related symptoms.
        </p>
        <p>
         A 2016 meta-analysis of individual data from 1620 patients with cerebral CMs reported the clinical course from CM diagnosis to the first CM treatment or last available follow-up. With a median follow-up of 3.5 years, symptomatic ICH developed in 204 patients, with an estimated five-year risk of 15.8 percent (95% CI 13.7-17.9) [
         <a href="#rid51">
          51
         </a>
         ]. Presentation with ICH and brainstem location appear to be risk factors for subsequent hemorrhage [
         <a href="#rid51">
          51,52
         </a>
         ]. According to the meta-analysis, the estimated five-year risk of ICH in these risk categories are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonbrainstem CMs presenting without ICH or focal neurologic deficit – 3.8 percent (95% CI 2.1-5.5)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brainstem CMs presenting without ICH or focal neurologic deficit – 8 percent (95% CI 0.1-15.9)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonbrainstem CMs presenting with ICH or focal neurologic deficits – 18.4 percent (95% CI 13.3.-23.5)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brainstem CMs presenting with ICH or focal neurologic deficits – 30.8 percent (95% CI 26.3-35.2)
        </p>
        <p>
        </p>
        <p>
         There was no independent prognostic significance for risk related to age, sex, or CM multiplicity [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         It is uncertain if the presence of a DVA is a risk factor for future hemorrhage. Retrospective studies have suggested that an associated DVA is a risk factor for hemorrhage at presentation [
         <a href="#rid33">
          33,53
         </a>
         ]. However, in one registry of 731 patients with sporadic cerebral CM, associated DVAs were negatively correlated with initial ICH (odds ratio [OR] 0.635, 95% CI 0.459-0.878) and were also not predictive of subsequent hemorrhage [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2405253436">
         <span class="h4">
          Efficacy of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no randomized controlled trials of interventions for CMs, but observational data from uncontrolled case series suggest that surgical resection is beneficial for select patients with CMs. A 2022 systematic review and meta-analysis identified 100 cohorts with nearly 9000 patients who had treatment of cerebral CMs [
         <a href="#rid54">
          54
         </a>
         ]. With a mean follow-up of 4 years, the mean hemorrhage rate was lower for patients who underwent surgery (2.6 percent) compared with those treated with radiosurgery or conservative treatment (14 and 22 percent, respectively). Prior hemorrhage and brainstem location were associated with higher bleeding risk in both nonsurgical patients and those treated with surgery or radiosurgery.
        </p>
        <p>
         In an earlier systematic review involving over 3400 patients with CM, the incidence of the composite outcome (death, nonfatal intracranial hemorrhage, or new/worse persistent focal neurological deficit) after neurosurgical resection was 6.6 per 100 person-years (95% CI 5.7-7.5) [
         <a href="#rid55">
          55
         </a>
         ]. The incidence increased with each percentage point increase in patients with brainstem CMs (rate ratio [RR] 1.03, 95% CI 1.01-1.05) and decreased with each percentage point increase in patients who presented with hemorrhage (RR 0.98, 95% CI 0.96-1.00) and with each more recent study midyear, defined as the middle of the time frame of the year in which treatment took place (RR 0.91, 95% CI 0.85-0.98).
        </p>
        <p>
         Thus, although direct comparisons are lacking and data are observational, indirect comparisons suggest that the overall risks at approximately three years of surgical excision (approximately 7 percent risk of death, nonfatal stroke, or neurologic deficit) compares favorably to the overall estimated five-year ICH recurrence risk, which in one cohort was as high as 29.5 percent [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         The inherent risks of surgery are higher with CMs removed from eloquent ares of the brain (ie, brain regions that directly control neurologic functions such as language, vision, movement, or sensation) or deep brain regions, particularly with brainstem lesions. In a 2019 systematic review of surgical resection of brainstem CMs involving 2493 adult and pediatric patients, the rate of early postoperative morbidity was 35 percent; at last follow-up, neurologic function was improved in 58 percent, stable in 26 percent, and worse in 12 percent, with a mortality rate of approximately 2 percent [
         <a href="#rid57">
          57
         </a>
         ]. Therefore, surgery is typically reserved for patients with a second symptomatic hemorrhage involving brainstem or deep CMs, whereas surgery is usually recommended after a first symptomatic hemorrhage for CMs in noneloquent, superficial locations [
         <a href="#rid6">
          6
         </a>
         ]. However, due to their aggressive natural history, some experts advise treating brainstem CMs even in the absence of recurrent hemorrhage when there is neurologic deterioration if the lesion is surgically accessible (ie, near the pial surface or via a noneloquent tissue corridor to the lesion) [
         <a href="#rid58">
          58
         </a>
         ]. Microsurgical techniques are also being used with success in some centers for patients with several hemorrhages or progression of symptoms [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3513318661">
         <span class="h4">
          Role of stereotactic radiosurgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <strong>
          not
         </strong>
         using stereotactic radiosurgery as the primary treatment for CMs. Stereotactic radiosurgery is a potential alternative to conservative therapy in patients with such surgically inaccessible lesions, and the available evidence suggests that it does lead to a reduction in hemorrhage, especially two years or more after radiosurgery [
         <a href="#rid60">
          60
         </a>
         ]. Nevertheless, high complication rates in available published series coupled with clinical experience has dissuaded many from using stereotactic radiosurgery for the treatment of CMs. In addition, there is concern that radiation exposure may promote the development of new CMs in familial cases [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">
          "Stereotactic cranial radiosurgery"
         </a>
         .)
        </p>
        <p>
         As an example, one retrospective analysis of 95 patients with 98 lesions found that stereotactic radiosurgery was associated with a significant drop in the annualized hemorrhage rate from 17 to 5 percent after a two-year post-treatment latency period [
         <a href="#rid61">
          61
         </a>
         ]. However, at an average follow-up of 5.4 years, the incidence of permanent neurologic deficit and mortality was 16 and 3 percent, respectively, and these complications were attributed to radiation-induced injury. In addition, the combined effects of radiation-related injury and clinical progression of the lesion led to a significant decline in neurologic function during follow-up. In a 2019 systematic review and meta-analysis of 14 observational studies with 576 patients who had stereotactic radiosurgery for brainstem CMs, symptomatic adverse radiation effects developed in 7.3 percent, and permanent adverse radiation effects were noted in 2.2 percent [
         <a href="#rid60">
          60
         </a>
         ]. However, data regarding the long-term safety and adverse effects of stereotactic radiosurgery remain sparse [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1789696330">
         <span class="h4">
          Management of epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a first seizure related to cerebral CM should be managed with medical therapy using antiseizure medication. In one prospective report of patients with a first CM-related seizure, the risk of developing epilepsy was 94 percent [
         <a href="#rid62">
          62
         </a>
         ], warranting the diagnosis of probable epilepsy after a single seizure and supporting the use of antiseizure medication treatment [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         In contrast, prophylactic antiseizure medication treatment is not indicated for patients with asymptomatic or symptomatic CMs who do not have seizures [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Medically refractory epilepsy is an indication for surgical resection [
         <a href="#rid6">
          6,63
         </a>
         ]. In a case series of 168 patients with symptomatic epilepsy attributed to CM, more than two-thirds of patients were seizure free at three years after surgery [
         <a href="#rid64">
          64
         </a>
         ]. Predictors for good outcome included mesiotemporal location, size &lt;1.5 cm, and the absence of secondarily generalized seizures. Another series identified a long preoperative seizure history and poorer preoperative seizure control as unfavorable prognostic indicators [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Epilepsy surgery is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">
          "Surgical treatment of epilepsy in adults", section on 'Vascular malformations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1486585692">
         <span class="h3">
          Management during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational data from several large series suggest that the risk of developing clinical symptoms due to cerebral CMs during pregnancy is similar to the baseline risk before pregnancy [
         <a href="#rid6">
          6,66-68
         </a>
         ], but this view is not universally held [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         For patients with cerebral CMs who develop new focal neurologic deficit, acute severe headache, or worsening seizures during pregnancy, a brain MRI is indicated to determine if the symptoms are related to CMs or another intracranial etiology [
         <a href="#rid6">
          6
         </a>
         ]. The approach to managing a new CM-related brain hemorrhage during pregnancy should account for the additional risk that surgical intervention may have on the pregnancy and the unborn child, but otherwise is similar to that in the nonpregnant state [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Females with epilepsy related to cerebral CMs should be evaluated and counseled, ideally before conception, about the risks associated with epilepsy during pregnancy. These include the potential for perinatal complications, seizure worsening, and adverse effects of antiseizure medications on the fetus and later development. These risks may be minimized by interventions before and during pregnancy, as reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">
          "Management of epilepsy during preconception, pregnancy, and the postpartum period"
         </a>
         .)
        </p>
        <p>
         The mode of delivery should be dictated by obstetrical indications; most patients can have a normal vaginal delivery unless there is a recent intracranial hemorrhage or a precluding neurologic deficit [
         <a href="#rid6">
          6,68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H968477253">
         <span class="h3">
          Safety of antithrombotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to conventional wisdom, the available data suggest that the bleeding risk associated with CMs is not increased with the use of antithrombotic or oral anticoagulant therapy [
         <a href="#rid71">
          71,72
         </a>
         ]. In a population-based cohort study of 300 prospectively identified people (age 16 years and older) in Scotland who were diagnosed with a cerebral CM, there were 61 who used antithrombotic therapy (including 10 who used anticoagulant therapy) [
         <a href="#rid73">
          73
         </a>
         ]. Compared with no antithrombotics, the use of antithrombotics was associated with a
         <strong>
          lower
         </strong>
         risk of subsequent intracranial hemorrhage or focal neurologic deficit (2 versus 12 percent; adjusted hazard ratio [HR] 0.12, 95% CI 0.02-0.88). Similarly, in a meta-analysis performed by the same investigators of six studies, mainly retrospective, with over 1300 patients, antithrombotic therapy use was associated with a lower risk of intracranial hemorrhage (3 versus 14 percent; incidence rate ratio 0.25, 95% CI 0.13-0.51). It is likely that the indication for antithrombotic therapy in the patients so treated was the prevention of arterial or venous occlusive disease, but individual patient data were not available; these results do
         <strong>
          not
         </strong>
         provide a rationale for treating CMs with antithrombotic therapy.
        </p>
        <p class="headingAnchor" id="H2483183803">
         <span class="h3">
          Use of contraceptive and menopausal hormonal medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data suggest use of hormonal contraception or menopausal therapy is associated with an elevated risk of hemorrhage [
         <a href="#rid74">
          74,75
         </a>
         ]. In a multicenter cohort study of 722 female patients with CM, the incidence rate of symptomatic hemorrhage was elevated among patients using hormonal therapy (7.4 versus 5.1 per 100 person-years) [
         <a href="#rid75">
          75
         </a>
         ]. Mean follow-up was 3.3 years. Hormonal therapy included estrogen and/or progesterone and most patients were taking an oral agent. This elevated risk of hemorrhage was present among both patients &lt;45 years old taking oral contraception (aHR 2.0, 95% CI 1.3-3.2) and those ≥45 years old taking menopausal therapy (aHR 2.4, 95% CI 1.1-5.1). These data are limited by nonrandomized study design, relatively short-term follow-up, and heterogeneity of both hormonal therapy and CM features.
        </p>
        <p>
         The use of hormonal contraceptive or menopausal therapy in patients with CM should be individualized, after informed discussion of risks and benefits. Nonhormonal options may be preferred for patients with CM to reduce the risk of hemorrhage.
        </p>
        <p class="headingAnchor" id="H2366624724">
         <span class="h1">
          DEVELOPMENTAL VENOUS ANOMALIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Developmental venous anomalies (DVAs) are composed of a radially arranged configuration of medullary veins ("caput medusae") separated by normal brain parenchyma (most commonly white matter) [
         <a href="#rid76">
          76
         </a>
         ]. These small venous conduits empty into a dilated superficial or deep vein that drains normal brain. A stenosis is common on the collecting vein at the point of penetration into the draining dural sinus. Microscopically, the venous structures appear largely normal with rare degenerative changes consisting of thickening and hyalinization. The lesions are common in supratentorial regions of the brain, with a frontal lobe predominance, but may also be found in the cerebellum and basis pontis.
        </p>
        <p>
         DVAs most often are solitary, although multiple lesions have been described in association with other clinical syndromes (eg, the blue rubber bleb nevus syndrome) [
         <a href="#rid77">
          77
         </a>
         ]. DVAs also may occur concurrently with cavernous malformations (CMs) in 13 to 40 percent, as well as with other intracranial vascular malformations and with superficial venous malformations of the head and neck [
         <a href="#rid32">
          32,78,79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2722546623">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         DVAs are considered benign lesions, although they may uncommonly present with seizures, progressive neurologic deficits, and hemorrhage [
         <a href="#rid52">
          52,76,80-83
         </a>
         ]. Headache is the most common presenting complaint, followed by seizures and sensory-motor phenomena. However, a direct correlation between these symptoms and the DVA is uncertain [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
         In a 10-year prospective clinical and MRI study involving 80 patients, a symptomatic hemorrhage rate of 0.34 percent per year was observed [
         <a href="#rid84">
          84
         </a>
         ]. In another study of 93 patients with 492 person-years of follow-up, no symptomatic hemorrhages occurred [
         <a href="#rid83">
          83
         </a>
         ]. The hemorrhages were usually minor, although fatal intracranial hemorrhages have been described [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         A retrospective case series reviewed the clinical presentations of 68 patients with imaging findings suggestive of DVAs whose symptoms could not be attributed to other pathologies [
         <a href="#rid86">
          86
         </a>
         ]. Cases with associated CMs were excluded. Two major pathophysiologic mechanisms were reported:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical compression of intracranial structures by a component of the vein was seen in 21 percent. The most common associated symptoms were hydrocephalus, tinnitus, brainstem deficits, hemifacial spasm, and trigeminal neuralgia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow-related symptoms were present in 72 percent. Increased inflow was present in 28 percent, typically related to an arteriovenous malformation (AVM) draining via dilated and ectatic medullary veins, resulting parenchymal and/or intraventricular hemorrhage, or venous infarction.
         <em>
         </em>
         Symptoms included headaches, neurologic deficits, seizures, and coma. Restricted outflow, either by an anatomic obstruction (eg, stenosis or thrombosis of the vein) in 38 percent or by a physiologic obstruction (eg, increased venous pressure secondary to a distal arteriovenous shunt or AVM) was observed in 6 percent. Patients presented with variable combinations of neurologic deficits, headaches, seizures, and altered mentation, a clinical picture that resembled that of cerebral venous thrombosis, with increased intracranial pressure, venous congestive edema, and/or intraparenchymal or subarachnoid hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No obvious alteration was found to explain symptoms in 9 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2574762305">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral angiography is considered the gold standard for the diagnosis of DVAs, but they are usually identified with contrast-enhanced cross-sectional imaging modalities such as CT, MRI, and magnetic resonance angiography (MRA) [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Computed tomography
         </strong>
         – Nonenhanced CT scans do not usually demonstrate DVAs unless there is an associated cavernous malformation. After contrast administration, the enlarged vein is all that is typically identified. CT angiography (CTA) has also been used to identify DVAs  (
         <a class="graphic graphic_diagnosticimage graphicRef139104" href="/z/d/graphic/139104.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnetic resonance imaging and angiography
         </strong>
         – MRI with gadolinium typically shows medullary veins in "caput medusae" pattern that converge on a dilated transcerebral draining vein. A characteristic "sunburst" pattern is seen on enhanced T1-weighted images  (
         <a class="graphic graphic_diagnosticimage graphicRef122040" href="/z/d/graphic/122040.html" rel="external">
          image 7
         </a>
         ) [
         <a href="#rid88">
          88
         </a>
         ]. Gradient echo sequences should be included to increase sensitivity for detecting associated CMs [
         <a href="#rid78">
          78
         </a>
         ]. White matter abnormalities and/or calcifications may be observed in the parenchyma adjacent to the DVA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MRA usually demonstrates the dilated venous channel with variable depiction of the smaller medullary veins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catheter angiography
         </strong>
         – Cerebral angiography usually is not needed for the diagnosis of DVA since MRI is often sufficient to make the diagnosis. In atypical cases, angiographic findings are pathognomonic; during the late capillary or venous phase there is a paucity of normal veins in the region of the lesion and a characteristic "caput medusae" appearance of the radially arranged small medullary veins  (
         <a class="graphic graphic_diagnosticimage graphicRef56038" href="/z/d/graphic/56038.html" rel="external">
          image 8
         </a>
         ). The arterial phase is typically normal; however, so-called arterialized DVAs have been described with early-phase opacification on angiography and/or enlarged arterial feeders [
         <a href="#rid78">
          78
         </a>
         ]. These lesions may have a bleeding risk that is more similar to an arteriovenous malformation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3223399084">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         DVAs should be treated conservatively in the vast majority of cases, with associated symptoms such as headaches and seizures managed medically [
         <a href="#rid85">
          85
         </a>
         ]. Obliteration may be considered in the rare patient with hemorrhage or uncontrolled seizures associated with a DVA [
         <a href="#rid82">
          82
         </a>
         ]. However, surgical or endovascular obliteration is associated with a risk of venous infarction [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         In patients who undergo surgery, preoperative MRI with gadolinium is required to identify an associated cavernous malformation [
         <a href="#rid32">
          32
         </a>
         ]. Venous infarction has been reported with DVA resection [
         <a href="#rid46">
          46
         </a>
         ]; thus, it is reasonable to simply evacuate the hematoma and leave the DVA in situ. Radiosurgical and endovascular techniques do not have a defined role in the management of these lesions.
        </p>
        <p>
         In rare patients who present with symptomatic thrombosis of a DVA, there is anecdotal support for considering the use of systematic anticoagulation [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1109.html" rel="external">
          "Cerebral venous thrombosis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3433292222">
         <span class="h1">
          CAPILLARY TELANGIECTASIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Capillary telangiectasias are small lesions most commonly found in the pons, middle cerebellar peduncles, and cerebellar dentate nuclei. Multiple lesions are common.
        </p>
        <p>
         The lesions are composed of small, dilated capillaries devoid of smooth muscle or elastic fibers. The intervening brain is often normal; it may also demonstrate areas of microhemorrhage or gliosis. A common histopathological feature of these lesions is a dilated efferent system, probably representing a venous channel.
        </p>
        <p>
         An argument has been made for these lesions representing the early stage in the spectrum of development of cavernous malformations and other "mixed" vascular malformations [
         <a href="#rid26">
          26,89
         </a>
         ]. Although not proven, angiogenesis is believed to play a role in lesion evolution. Most telangiectasias represent an angiodysplastic phenomenon resulting from faulty embryogenesis of the vascular wall and have been associated with angiomatous phacomatoses such as Osler-Weber-Rendu (hereditary hemorrhagic telangiectasia), Louis-Bar (ataxia-telangiectasia), and Wyburn-Mason (unilateral retinocephalic vascular malformation) syndromes [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Cerebral vascular abnormalities'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia", section on 'Neuroimaging features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H878977148">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Capillary telangiectasias are usually clinically silent, found incidentally on neuroimaging studies or at postmortem examination. In a systematic review of 10 series and 203 patients with capillary telangiectasias, symptomatic cases accounted for 6 percent [
         <a href="#rid91">
          91
         </a>
         ]; headache, nausea, and seizures have been described in patients with these lesions, although a causal relationship is unclear.
        </p>
        <p class="headingAnchor" id="H1298497411">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI with gadolinium contrast is the most sensitive imaging modality for the identification of brain capillary telangiectasias, but the lesions may be inconspicuous on precontrast MRI. Small lesions that are hypo- to isointense on T1-weighted sequences and iso- to slightly hyperintense on T2-weighted sequences with faint enhancement on postcontrast T1-weghted sequences are suggestive, although not diagnostic, of these lesions [
         <a href="#rid92">
          92
         </a>
         ]. Compared with other precontrast MRI sequences, sensitivity for the detection of capillary telangiectasias is increased with the use of gradient echo and especially with susceptibility-weighted imaging (SWI)  (
         <a class="graphic graphic_diagnosticimage graphicRef122043" href="/z/d/graphic/122043.html" rel="external">
          image 9
         </a>
         ) [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p>
         Telangiectasias can be identified in the late arterial/early capillary phase of angiography as a faint blush with an associated venous channel. Thus, these lesions can be distinguished from developmental venous anomalies that are visualized during the venous phase of the study.
        </p>
        <p class="headingAnchor" id="H733046883">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Capillary telangiectasias are nonoperable lesions. Management is conservative, particularly since most lesions are asymptomatic.
        </p>
        <p>
         The routine care and additional screening for patients with capillary telangiectasias associated with other conditions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">
          "Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2203045236">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">
          "Society guideline links: Stroke in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119057.html" rel="external">
          "Society guideline links: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H99004141">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17183.html" rel="external">
          "Patient education: Arteriovenous malformations in the brain (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26648821">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain arteriovenous malformations
         </strong>
         – Arteriovenous malformations are the most dangerous cerebral vascular malformation and can cause hemorrhage, seizures, headaches, and focal neurologic deficits. These lesions are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">
          "Brain arteriovenous malformations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cavernous malformations
         </strong>
         – Cavernous malformations are thin-walled dilated capillaries with a simple endothelial lining  (
         <a class="graphic graphic_diagnosticimage graphicRef80348" href="/z/d/graphic/80348.html" rel="external">
          image 1
         </a>
         ). They may occur as a sporadic or familial condition and may be associated with developmental venous anomalies in about 25 percent. (See
         <a class="local">
          'Cavernous malformations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cavernous malformations may be found incidentally on neuroimaging or may present with neurologic symptoms such as hemorrhage, seizures, and/or progressive neurologic deficits  (
         <a class="graphic graphic_diagnosticimage graphicRef68000" href="/z/d/graphic/68000.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef139103" href="/z/d/graphic/139103.html" rel="external">
          image 2
         </a>
         ). Recurrent hemorrhage is more common after an initial bleed and may be as high as 5 percent per year for supratentorial lesions and 21 percent for brainstem lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cavernous malformations are typically identified on MRI and are often angiographically occult. They can occur throughout the brain but are most common in the subcortical rolandic and temporal areas.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asymptomatic cavernous malformations are generally followed without intervention. Surgical resection may be indicated for accessible symptomatic lesions associated with progressive neurologic deficits, intractable epilepsy, and/or hemorrhage. Stereotactic radiosurgery is an option for nonoperable lesions, but long-term safety is uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Developmental venous anomalies
         </strong>
         – Developmental venous anomalies (DVAs) consist of a radially arranged configuration of medullary veins separated by normal brain parenchyma  (
         <a class="graphic graphic_diagnosticimage graphicRef122040" href="/z/d/graphic/122040.html" rel="external">
          image 7
         </a>
         ). The lesions are usually solitary but can be multiple and occur with cavernous malformations. (See
         <a class="local">
          'Developmental venous anomalies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DVAs are usually an incidental finding but may rarely present with seizures or hemorrhage. They are usually identified on MRI. Cerebral angiography is considered the gold standard for diagnosis of a DVA. After diagnosis, hemorrhage is unusual.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients with DVAs are followed without intervention; rarely, surgery is required for hemorrhage or intractable epilepsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Capillary telangiectasias
         </strong>
         – Capillary telangiectasias are small, dilated capillaries devoid of smooth muscle or elastic fibers. (See
         <a class="local">
          'Capillary telangiectasias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MRI is the most sensitive imaging modality for the identification of brain capillary telangiectasias  (
         <a class="graphic graphic_diagnosticimage graphicRef122043" href="/z/d/graphic/122043.html" rel="external">
          image 9
         </a>
         ). They are most commonly found in the pons, middle cerebellar peduncles, and dentate nuclei. Multiple lesions are common.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Capillary telangiectasias are usually clinically silent, found incidentally on neuroimaging studies. They are not associated with morbidity, and intervention is not required.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           el-Gohary EG, Tomita T, Gutierrez FA, McLone DG. Angiographically occult vascular malformations in childhood. Neurosurgery 1987; 20:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormick WF. The pathology of vascular ("arteriovenous") malformations. J Neurosurg 1966; 24:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Shahi R, Bhattacharya JJ, Currie DG, et al. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). Stroke 2003; 34:1163.
          </a>
         </li>
         <li class="breakAll">
          McCormick WF. Pathology of vascular malformations of the brain. In: Intracranial Arteriovenous Malformations, Wilson CB, Stein BM (Eds), Williams &amp; Wilkins, Baltimore 1984. p.44.
         </li>
         <li class="breakAll">
          Russell DS, Rubinstein LJ. Pathology of Tumors of the Nervous System, 5th ed, Williams &amp; Wilkins, Baltimore 1989. p.727.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akers A, Al-Shahi Salman R, A Awad I, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017; 80:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choquet H, Pawlikowska L, Lawton MT, Kim H. Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci 2015; 59:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim J. Introduction to cerebral cavernous malformation: a brief review. BMB Rep 2016; 49:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zafar A, Quadri SA, Farooqui M, et al. Familial Cerebral Cavernous Malformations. Stroke 2019; 50:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chohan MO, Marchiò S, Morrison LA, et al. Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review. JAMA Neurol 2019; 76:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher OS, Boggon TJ. Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. Cell Mol Life Sci 2014; 71:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haasdijk RA, Cheng C, Maat-Kievit AJ, Duckers HJ. Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management. Eur J Hum Genet 2012; 20:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubovsky J, Zabramski JM, Kurth J, et al. A gene responsible for cavernous malformations of the brain maps to chromosome 7q. Hum Mol Genet 1995; 4:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laberge-le Couteulx S, Jung HH, Labauge P, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999; 23:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verlaan DJ, Davenport WJ, Stefan H, et al. Cerebral cavernous malformations: mutations in Krit1. Neurology 2002; 58:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig HD, Günel M, Cepeda O, et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998; 7:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergametti F, Denier C, Labauge P, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 1988; 319:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fritschi JA, Reulen HJ, Spetzler RF, Zabramski JM. Cavernous malformations of the brain stem. A review of 139 cases. Acta Neurochir (Wien) 1994; 130:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gastelum E, Sear K, Hills N, et al. Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. J Child Neurol 2015; 30:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyre M, Miyagishima D, Bielle F, et al. Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. N Engl J Med 2021; 385:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong T, Xiao X, Ren J, et al. Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations. Brain 2021; 144:2648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald DA, Shi C, Shenkar R, et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet 2014; 23:4357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol 2005; 63:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frischer JM, Pipp I, Stavrou I, et al. Cerebral cavernous malformations: congruency of histopathological features with the current clinical definition. J Neurol Neurosurg Psychiatry 2008; 79:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigamonti D, Johnson PC, Spetzler RF, et al. Cavernous malformations and capillary telangiectasia: a spectrum within a single pathological entity. Neurosurgery 1991; 28:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson FH, Houser OW, Scheithauer BW, et al. Angiographically occult vascular malformations: a correlative study of features on magnetic resonance imaging and histological examination. Neurosurgery 1994; 34:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Runnels JB, Gifford DB, Forsberg PL, Hanbery JW. Dense calcification in a large cavernous angioma. Case report. J Neurosurg 1969; 30:293.
          </a>
         </li>
         <li class="breakAll">
          McCormick, PC, Michelson, WJ. Management of intracranial cavernous and venous malformations. In: Intracranial Vascular Malformations, Barrow, DL (Ed), American Association of Neurological Surgeons. Park Ridge, IL 1990. p.197.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badhiwala JH, Farrokhyar F, Alhazzani W, et al. Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data: Clinic article. J Neurosurg Spine 2014; 21:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otten M, Mccormick P. Natural history of spinal cavernous malformations. Handb Clin Neurol 2017; 143:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe T, Singer RJ, Marks MP, et al. Coexistence of occult vascular malformations and developmental venous anomalies in the central nervous system: MR evaluation. AJNR Am J Neuroradiol 1998; 19:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamezawa T, Hamada J, Niiro M, et al. Clinical implications of associated venous drainage in patients with cavernous malformation. J Neurosurg 2005; 102:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dammann P, Wrede KH, Maderwald S, et al. The venous angioarchitecture of sporadic cerebral cavernous malformations: a susceptibility weighted imaging study at 7 T MRI. J Neurol Neurosurg Psychiatry 2013; 84:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol 2010; 31:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein HE, Solomon RA. Epidemiology of cavernous malformations. Handb Clin Neurol 2017; 143:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Curling O Jr, Kelly DL Jr, Elster AD, Craven TE. An analysis of the natural history of cavernous angiomas. J Neurosurg 1991; 75:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 1991; 75:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ene C, Kaul A, Kim L. Natural history of cerebral cavernous malformations. Handb Clin Neurol 2017; 143:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flemming KD. Incidence, Prevalence, and Clinical Presentation of Cerebral Cavernous Malformations. Methods Mol Biol 2020; 2152:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batra S, Lin D, Recinos PF, et al. Cavernous malformations: natural history, diagnosis and treatment. Nat Rev Neurol 2009; 5:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiba T, Tanaka R, Koike T, et al. Natural history of intracranial cavernous malformations. J Neurosurg 1995; 83:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang KY, Idowu OR, Lin DDM. Radiology and imaging for cavernous malformations. Handb Clin Neurol 2017; 143:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokin M, Agazzi S, Dawson L, Primiani CT. Neuroimaging of Cavernous Malformations. Curr Pain Headache Rep 2017; 21:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Li W, Tong KA, et al. Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging 2015; 42:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senegor M, Dohrmann GJ, Wollmann RL. Venous angiomas of the posterior fossa should be considered as anomalous venous drainage. Surg Neurol 1983; 19:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sze G, Krol G, Olsen WL, et al. Hemorrhagic neoplasms: MR mimics of occult vascular malformations. AJR Am J Roentgenol 1987; 149:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves VT, Reis F, Queiroz Lde S, França M Jr. Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation. Arq Neuropsiquiatr 2013; 71:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DR, Giannini C, Jenkins RB, et al. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 2019; 61:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mouchtouris N, Chalouhi N, Chitale A, et al. Management of cerebral cavernous malformations: from diagnosis to treatment. ScientificWorldJournal 2015; 2015:808314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horne MA, Flemming KD, Su IC, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol 2016; 15:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen B, Herten A, Saban D, et al. Hemorrhage from cerebral cavernous malformations: The role of associated developmental venous anomalies. Neurology 2020; 95:e89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashefiolasl S, Bruder M, Brawanski N, et al. A benchmark approach to hemorrhage risk management of cavernous malformations. Neurology 2018; 90:e856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bubenikova A, Skalicky P, Benes V Jr, et al. Overview of cerebral cavernous malformations: comparison of treatment approaches. J Neurol Neurosurg Psychiatry 2022; 93:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poorthuis MH, Klijn CJ, Algra A, et al. Treatment of cerebral cavernous malformations: a systematic review and meta-regression analysis. J Neurol Neurosurg Psychiatry 2014; 85:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Shahi Salman R, Hall JM, Horne MA, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol 2012; 11:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearns KN, Chen CJ, Tvrdik P, et al. Outcomes of Surgery for Brainstem Cavernous Malformations: A Systematic Review. Stroke 2019; 50:2964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman RS, Spetzler RF, Lee KS, et al. Cavernous malformations of the brain stem. J Neurosurg 1991; 75:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandalcioglu IE, Wiedemayer H, Secer S, et al. Surgical removal of brain stem cavernous malformations: surgical indications, technical considerations, and results. J Neurol Neurosurg Psychiatry 2002; 72:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim BS, Kim KH, Lee MH, Lee JI. Stereotactic Radiosurgery for Brainstem Cavernous Malformations: An Updated Systematic Review and Meta-Analysis. World Neurosurg 2019; 130:e648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin-Hanjani S, Ogilvy CS, Candia GJ, et al. Stereotactic radiosurgery for cavernous malformations: Kjellberg's experience with proton beam therapy in 98 cases at the Harvard Cyclotron. Neurosurgery 1998; 42:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Josephson CB, Leach JP, Duncan R, et al. Seizure risk from cavernous or arteriovenous malformations: prospective population-based study. Neurology 2011; 76:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenow F, Alonso-Vanegas MA, Baumgartner C, et al. Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2013; 54:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann CR, Acciarri N, Bertalanffy H, et al. Seizure outcome after resection of supratentorial cavernous malformations: a study of 168 patients. Epilepsia 2007; 48:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen DS, Zubay GP, Goodman RR. Seizure outcome after lesionectomy for cavernous malformations. J Neurosurg 1995; 83:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalani MY, Zabramski JM. Risk for symptomatic hemorrhage of cerebral cavernous malformations during pregnancy. J Neurosurg 2013; 118:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witiw CD, Abou-Hamden A, Kulkarni AV, et al. Cerebral cavernous malformations and pregnancy:  hemorrhage risk and influence on obstetrical management. Neurosurgery 2012; 71:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph NK, Kumar S, Brown RD Jr, et al. Influence of Pregnancy on Hemorrhage Risk in Women With Cerebral and Spinal Cavernous Malformations. Stroke 2021; 52:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada S, Nakase H, Nakagawa I, et al. Cavernous malformations in pregnancy. Neurol Med Chir (Tokyo) 2013; 53:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Can A, Du R. Neurosurgical Issues in Pregnancy. Semin Neurol 2017; 37:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneble HM, Soumare A, Hervé D, et al. Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke 2012; 43:3196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flemming KD, Link MJ, Christianson TJ, Brown RD Jr. Use of antithrombotic agents in patients with intracerebral cavernous malformations. J Neurosurg 2013; 118:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuurbier SM, Hickman CR, Tolias CS, et al. Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol 2019; 18:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flemming KD, Kumar S, Brown RD Jr, Lanzino G. Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations. World Neurosurg 2020; 133:e767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuurbier SM, Santos AN, Flemming KD, et al. Female Hormone Therapy and Risk of Intracranial Hemorrhage From Cerebral Cavernous Malformations: A Multicenter Observational Cohort Study. Neurology 2023; 100:e1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mooney MA, Zabramski JM. Developmental venous anomalies. Handb Clin Neurol 2017; 143:279.
          </a>
         </li>
         <li class="breakAll">
          Osborn AG. Intracranial vascular malformations. In: Diagnostic Neuroradiology, Osborn AG (Ed), Mosby Year-Book, St. Louis 1994. p.316.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruíz DS, Yilmaz H, Gailloud P. Cerebral developmental venous anomalies: current concepts. Ann Neurol 2009; 66:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boukobza M, Enjolras O, Guichard JP, et al. Cerebral developmental venous anomalies associated with head and neck venous malformations. AJNR Am J Neuroradiol 1996; 17:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numaguchi Y, Kitamura K, Fukui M, et al. Intracranial venous angiomas. Surg Neurol 1982; 18:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothfus WE, Albright AL, Casey KF, et al. Cerebellar venous angioma: "benign" entity? AJNR Am J Neuroradiol 1984; 5:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik GM, Morgan JK, Boulos RS, Ausman JI. Venous angiomas: an underestimated cause of intracranial hemorrhage. Surg Neurol 1988; 30:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hon JM, Bhattacharya JJ, Counsell CE, et al. The presentation and clinical course of intracranial developmental venous anomalies in adults: a systematic review and prospective, population-based study. Stroke 2009; 40:1980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin MR, Kondziolka D, Flickinger JC, et al. The prospective natural history of cerebral venous malformations. Neurosurgery 1998; 43:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garner TB, Del Curling O Jr, Kelly DL Jr, Laster DW. The natural history of intracranial venous angiomas. J Neurosurg 1991; 75:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira VM, Geibprasert S, Krings T, et al. Pathomechanisms of symptomatic developmental venous anomalies. Stroke 2008; 39:3201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peebles TR, Vieco PT. Intracranial developmental venous anomalies: diagnosis using CT angiography. J Comput Assist Tomogr 1997; 21:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gökçe E, Acu B, Beyhan M, et al. Magnetic resonance imaging findings of developmental venous anomalies. Clin Neuroradiol 2014; 24:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeder P, Gudinchet F, Meuli R, de Tribolet N. Development of a cavernous malformation of the brain. AJNR Am J Neuroradiol 1998; 19:1141.
          </a>
         </li>
         <li class="breakAll">
          Garcia J, Anderson M. Circulatory disorders and their effects on the brain. In: Textbook of neuropathology, Davis R, Robertson D (Eds), Williams &amp; Wilkins, Baltimore 1991. p.625.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross BA, Puri AS, Popp AJ, Du R. Cerebral capillary telangiectasias: a meta-analysis and review of the literature. Neurosurg Rev 2013; 36:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee RR, Becher MW, Benson ML, Rigamonti D. Brain capillary telangiectasia: MR imaging appearance and clinicohistopathologic findings. Radiology 1997; 205:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry US, De Bruin DE, Policeni BA. Susceptibility-weighted MR imaging: a better technique in the detection of capillary telangiectasia compared with T2* gradient-echo. AJNR Am J Neuroradiol 2014; 35:2302.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1129 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3601023" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Angiographically occult vascular malformations in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5934138" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The pathology of vascular ("arteriovenous") malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702837" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702837" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702837" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28387823" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900426" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genetics of cerebral cavernous malformations: current status and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923303" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Introduction to cerebral cavernous malformation: a brief review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30909834" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Familial Cerebral Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476961" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24287896" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21829231" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cerebral cavernous malformations: from molecular pathogenesis to genetic counselling and clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795602" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A gene responsible for cavernous malformations of the brain maps to chromosome 7q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10508515" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11914398" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cerebral cavernous malformations: mutations in Krit1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9811928" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15543491" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3393196" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cerebral cavernous malformations. Incidence and familial occurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7725941" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cavernous malformations of the brain stem. A review of 139 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25122111" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34496175" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33729480" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24698976" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15808709" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Intracranial cavernous angioma: a practical review of clinical and biological aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17986498" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cerebral cavernous malformations: congruency of histopathological features with the current clinical definition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1994283" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cavernous malformations and capillary telangiectasia: a spectrum within a single pathological entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8052376" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Angiographically occult vascular malformations: a correlative study of features on magnetic resonance imaging and histological examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5780902" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Dense calcification in a large cavernous angioma. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5780902" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dense calcification in a large cavernous angioma. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25062285" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data: Clinic article.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552145" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Natural history of spinal cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9432157" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Coexistence of occult vascular malformations and developmental venous anomalies in the central nervous system: MR evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15658092" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical implications of associated venous drainage in patients with cavernous malformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23085932" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The venous angioarchitecture of sporadic cerebral cavernous malformations: a susceptibility weighted imaging study at 7 T MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833796" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552146" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Epidemiology of cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919691" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : An analysis of the natural history of cavernous angiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919692" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Natural history of the cavernous angioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552144" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Natural history of cerebral cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32524541" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidence, Prevalence, and Clinical Presentation of Cerebral Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19953116" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cavernous malformations: natural history, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7782850" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Natural history of intracranial cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552147" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Radiology and imaging for cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29030748" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Neuroimaging of Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25270052" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6828991" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Venous angiomas of the posterior fossa should be considered as anomalous venous drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3500614" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hemorrhagic neoplasms: MR mimics of occult vascular malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23249973" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pleomorphic xanthoastrocytoma: magnetic resonance imaging findings in a series of cases with histopathological confirmation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31396664" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25629087" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Management of cerebral cavernous malformations: from diagnosis to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26654287" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32513786" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hemorrhage from cerebral cavernous malformations: The role of associated developmental venous anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29429974" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A benchmark approach to hemorrhage risk management of cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35273070" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Overview of cerebral cavernous malformations: comparison of treatment approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24667206" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Treatment of cerebral cavernous malformations: a systematic review and meta-regression analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22297119" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31510895" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Outcomes of Surgery for Brainstem Cavernous Malformations: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2045915" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cavernous malformations of the brain stem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11861694" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Surgical removal of brain stem cavernous malformations: surgical indications, technical considerations, and results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31276856" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Stereotactic Radiosurgery for Brainstem Cavernous Malformations: An Updated Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632180" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Stereotactic radiosurgery for cavernous malformations: Kjellberg's experience with proton beam therapy in 98 cases at the Harvard Cyclotron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536634" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Seizure risk from cavernous or arteriovenous malformations: prospective population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24134485" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17346251" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Seizure outcome after resection of supratentorial cavernous malformations: a study of 168 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7616268" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Seizure outcome after lesionectomy for cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23039155" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Risk for symptomatic hemorrhage of cerebral cavernous malformations during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22710379" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cerebral cavernous malformations and pregnancy:  hemorrhage risk and influence on obstetrical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33493052" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Influence of Pregnancy on Hemorrhage Risk in Women With Cerebral and Spinal Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23979052" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cavernous malformations in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29270942" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Neurosurgical Issues in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23150651" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22998055" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Use of antithrombotic agents in patients with intracerebral cavernous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31401075" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31605843" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36754635" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Female Hormone Therapy and Risk of Intracranial Hemorrhage From Cerebral Cavernous Malformations: A Multicenter Observational Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552150" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Developmental venous anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28552150" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Developmental venous anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19798638" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cerebral developmental venous anomalies: current concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8733978" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cerebral developmental venous anomalies associated with head and neck venous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7179074" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Intracranial venous angiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6421127" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cerebellar venous angioma: "benign" entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3187879" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Venous angiomas: an underestimated cause of intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390075" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The presentation and clinical course of intracranial developmental venous anomalies in adults: a systematic review and prospective, population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9696070" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The prospective natural history of cerebral venous malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919693" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The natural history of intracranial venous angiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18988912" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pathomechanisms of symptomatic developmental venous anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9216761" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Intracranial developmental venous anomalies: diagnosis using CT angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24240482" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Magnetic resonance imaging findings of developmental venous anomalies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672028" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Development of a cavernous malformation of the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672028" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Development of a cavernous malformation of the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23192650" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Cerebral capillary telangiectasias: a meta-analysis and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9393538" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Brain capillary telangiectasia: MR imaging appearance and clinicohistopathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25147196" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Susceptibility-weighted MR imaging: a better technique in the detection of capillary telangiectasia compared with T2* gradient-echo.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
